ClinicalTrials.gg
CompletedNCT03165955Updated Mar 12, 2025Results posted

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

A Phase 1 interventional study of Oraxol in Breastcancer, sponsored by Health Hope Pharma. Completed at 6 sites in Taiwan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Health Hope Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 380 studies in Breast Neoplasms with a site in Taiwan — 68 open to participants now, 133 under way, 60 of them phase 3. Breast Neoplasms · Taiwan.

Enrollment
306th of 332
28 · median 222
Started
2017
with 17 others
Phase 1
25 of 380
none open now
Registered
156th of 380
by date

Among the 380 studies in Breast Neoplasms with a site in Taiwan, this one is the 306th largest by enrollment of the 332 interventional ones that give a count, is one of 18 that started in 2017, is one of 25 in phase 1, and was the 156th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

68 of the 380 studies in Breast Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 380 studies in Breast Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.

Read the detailed description

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment. If subjects achieve stable disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment Period, they may continue Oraxol treatment in a separate extension study.

03

Conditions studied

  • Breastcancer

Browse trials for

Keywords

  • breast cancer
  • paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written
  2. Women ≥18 years of age on day of consent
  3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist
  4. as per v1.1 criteria
  5. Adequate hematological status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) maintain:

    • (ANC) ≥1.5 x 10\^9/L
    • count ≥100 x 10\^9/L
    • (Hgb) ≥9 g/dL
  6. Adequate liver function

    • Total of ≤1.5 mg/dL
    • (ALT) and aspartate aminotransferase (AST) ≤3 x (ULN) or ≤5 x ULN if liver is present
    • Alkaline phosphatase (ALP) ≤3 x ULN or ≤5 x ULN if bone metastasis is present
    • Gamma glutamyl transferase (GGT) \<10 x ULN
  7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN
  8. (ECOG) performance status of 0 or 1
  9. of at least 3 months
  10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days
  11. Willing to abstain from alcohol consumption for 3 days before the first dose of study drug through the completion of the second inpatient PK sampling period
  12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing period through the completion of protocol-specified PK sampling for that week
  13. Subjects must be (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.
  14. Subjects who are of must have a negative serum pregnancy test at Screening and within 96 hours before dosing.

Exclusion criteria

Exclusion Criteria:

  1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous products (IPs)
  2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based chemotherapy or for disease, the subject less than 1 year following treatment
  3. Subjects unable to swallow study medication in its intact form or have malabsorption syndrome
  4. Only site of metastatic disease is unmeasurable according to v1.1 criteria
  5. Known , including
  6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer
  7. Are currently receiving other medications intended for the treatment of their
  8. Women who are pregnant or breastfeeding
  9. Taking prohibited medications:
  10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.
  11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements
  12. Known allergic reaction or intolerance to study medication components
  13. Known allergic reaction or intolerance to contrast media
  14. Subjects who, in the Investigator's opinion, are not suitable for participation in this study
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Oraxol

    Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.

    Drug: Oraxol

Interventions

  • DrugOraxol

    HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules

    Also known as: HM30181 methanesulfonate monohydrate, Oral paclitaxel capsules

06

What researchers measure

Primary outcomes

  1. PK Parameters for paclitaxel_AUC (0-52)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  2. PK Parameters for paclitaxel_Cmax

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  3. PK Parameters for paclitaxel_Ctrough(24)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  4. PK Parameters for paclitaxel_Ctrough(48)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  5. PK Parameters for paclitaxel_Cmax(0-24)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  6. PK Parameters for paclitaxel_Cmax(24-48)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  7. PK Parameters for paclitaxel_Cmax(48-52)

    PK parameters were summarized using the mean, SD

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  8. PK Parameters for paclitaxel_tmax(0-24)

    PK parameters were summarized using the median, minimum, maximum

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  9. PK Parameters for paclitaxel_tmax(24-48)

    PK parameters were summarized using the median, minimum, maximum

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

  10. PK Parameters for paclitaxel_tmax(48-52)

    PK parameters were summarized using the median, minimum, maximum

    Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4

Secondary outcomes

  1. Safety of Oraxol in Breast Cancer Patients

    Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).

    Time frame: From enrollment through study completion, approximately 17 weeks

  2. Response Rate

    Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.

    Time frame: From baseline through study completion, around 21 weeks

  3. Progression-free Survival

    PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation

    Time frame: From baseline through study completion, around 21 weeks

  4. Overall Survival

    OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation

    Time frame: From baseline through study completion, around 21 weeks

07

Results

Posted Jul 8, 2020

Participant flow

Screening/Baseline
Participant flow — Screening/Baseline
MilestoneOraxol (Oral Paclitaxel Plus HM30181)
Started31
Completed28
Not completed3
Treatment
Participant flow — Treatment
MilestoneOraxol (Oral Paclitaxel Plus HM30181)
Started28
Completed20
Not completed8
Withdrew: Withdrawal by subject3
Withdrew: Death1
Withdrew: Adverse event1
Withdrew: Progressive disease3

Outcome measures

PrimaryPK Parameters for paclitaxel_AUC (0-52)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng*hr/mL
PK Parameters for paclitaxel_AUC (0-52)
ng*hr/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 13419 ± 1475
Week 43224 ± 1150
PrimaryPK Parameters for paclitaxel_Cmax

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Cmax
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 1366 ± 143
Week 4356 ± 140
PrimaryPK Parameters for paclitaxel_Ctrough(24)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Ctrough(24)
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 111.0 ± 4.0
Week 412.5 ± 8.7
PrimaryPK Parameters for paclitaxel_Ctrough(48)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Ctrough(48)
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 112.6 ± 4.3
Week 411.7 ± 3.3
PrimaryPK Parameters for paclitaxel_Cmax(0-24)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Cmax(0-24)
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 1312 ± 132
Week 4267 ± 135
PrimaryPK Parameters for paclitaxel_Cmax(24-48)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Cmax(24-48)
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 1274 ± 144
Week 4298 ± 127
PrimaryPK Parameters for paclitaxel_Cmax(48-52)

PK parameters were summarized using the mean, SD

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Mean · ng/mL
PK Parameters for paclitaxel_Cmax(48-52)
ng/mLOraxol (Oral Paclitaxel Plus HM30181)
Week 1287 ± 144
Week 4288 ± 144
PrimaryPK Parameters for paclitaxel_tmax(0-24)

PK parameters were summarized using the median, minimum, maximum

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Median · hour
PK Parameters for paclitaxel_tmax(0-24)
hourOraxol (Oral Paclitaxel Plus HM30181)
Week 11.05 (0.97 to 2.12)
Week 41.07 (0.93 to 2.12)
PrimaryPK Parameters for paclitaxel_tmax(24-48)

PK parameters were summarized using the median, minimum, maximum

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Median · hour
PK Parameters for paclitaxel_tmax(24-48)
hourOraxol (Oral Paclitaxel Plus HM30181)
Week 125.03 (24.47 to 27.03)
Week 425.00 (22.78 to 27.33)
PrimaryPK Parameters for paclitaxel_tmax(48-52)

PK parameters were summarized using the median, minimum, maximum

Time frame:
PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Reported as:
Median · hour
PK Parameters for paclitaxel_tmax(48-52)
hourOraxol (Oral Paclitaxel Plus HM30181)
Week 149.02 (48.22 to 51.03)
Week 449.03 (47.05 to 51.05)
SecondarySafety of Oraxol in Breast Cancer Patients

Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).

Time frame:
From enrollment through study completion, approximately 17 weeks
Reported as:
Count of participants · Participants
Safety of Oraxol in Breast Cancer Patients
ParticipantsOraxol (Oral Paclitaxel Plus HM30181)
Subjects with At Least One TEAE27
TEAE leading to dose interruption or reduction19
TEAE leading to study drug discontinuation2
TEAE leading to discontinuation from the study2
Serious TEAE8
TEAE related to Oraxol27
TEAE related to progression of disease4
Death1
TEAE with action taken for other treatments24
Subjects with At Least One Grade ≥3 TEAE19
SecondaryResponse Rate

Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.

Time frame:
From baseline through study completion, around 21 weeks
Reported as:
Count of participants · Participants
Response Rate
ParticipantsOraxol (Oral Paclitaxel Plus HM30181)
Investigator Assessment — Complete response (CR)0
Investigator Assessment — Partial response (PR)11
Investigator Assessment — Stable disease (SD)13
Investigator Assessment — Progressive disease (PD)1
Investigator Assessment — Non-evaluable (NE)1
ICRRC Assessment — Complete response (CR)0
ICRRC Assessment — Partial response (PR)10
ICRRC Assessment — Stable disease (SD)12
ICRRC Assessment — Progressive disease (PD)3
ICRRC Assessment — Non-evaluable (NE)0
SecondaryProgression-free Survival

PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation

Time frame:
From baseline through study completion, around 21 weeks
Reported as:
Median · weeks
Progression-free Survival
weeksOraxol (Oral Paclitaxel Plus HM30181)
Investigator AssessmentNA (NA to NA)
ICRRC Assessment15.86 (15.00 to NA)
SecondaryOverall Survival

OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation

Time frame:
From baseline through study completion, around 21 weeks
Reported as:
Median · weeks
Overall Survival
weeksOraxol (Oral Paclitaxel Plus HM30181)
Overall SurvivalNA (NA to NA)

Adverse events

Collected over An AE was any untoward medical occurrence in a subject or clinical investigation subject, and included events occurring from the time a subject signed the ICF through the last subject contact. The period is up to 21 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oraxol (Oral Paclitaxel Plus HM30181)1/28 (3.6%)8/28 (28.6%)27/28 (96.4%)
Most frequent serious events
Most frequent serious events
EventOraxol (Oral Paclitaxel Plus HM30181)
NeutropeniaBlood and lymphatic system disorders3/28
Hepatitis acuteHepatobiliary disorders1/28
PneumoniaInfections and infestations1/28
Septic shockInfections and infestations1/28
Femur fractureInjury, poisoning and procedural complications1/28
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/28
Deep vein thrombosisVascular disorders1/28
Most frequent other events
Showing 10 of 28
Most frequent other events
EventOraxol (Oral Paclitaxel Plus HM30181)
DiarrhoeaGastrointestinal disorders16/28
NeutropeniaBlood and lymphatic system disorders16/28
AlopeciaSkin and subcutaneous tissue disorders12/28
NauseaGastrointestinal disorders9/28
AnaemiaBlood and lymphatic system disorders6/28
Alanine aminotransferase increasedInvestigations5/28
Aspartate aminotransferase increasedInvestigations5/28
VomitingGastrointestinal disorders4/28
Neuropathy peripheralNervous system disorders4/28
Decreased appetiteMetabolism and nutrition disorders4/28

Baseline characteristics

A total of 31 subjects were screened; 3 subjects were screen failures and were not included in the analysis

Age, Continuous
Age, Continuous(years)Oraxol (Oral Paclitaxel Plus HM30181)
Mean56.6 ± 9.04
Sex: Female, Male
Sex: Female, Male(Participants)Oraxol (Oral Paclitaxel Plus HM30181)
Female28
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oraxol (Oral Paclitaxel Plus HM30181)
American Indian or Alaska Native0
Asian28
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Oraxol (Oral Paclitaxel Plus HM30181)
Taiwan28
ECOG
ECOG(Participants)Oraxol (Oral Paclitaxel Plus HM30181)
024
14
08

Study locations

6 sites
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
  • Taipei Veterans Generla Hospital
    Taipei, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Shuang Ho Hospital
    Taipei, 23561, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2018, 18 months.

Results were first posted in Jul 2020, 1 year 7 months after primary completion.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 18 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2017
First posted
May 24, 2017
StartActual
May 9, 2017
Primary completionActual
Nov 22, 2018
CompletionActual
Nov 22, 2018
Results first posted
Jul 8, 2020
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03165955
Lead sponsor
Health Hope Pharma
Collaborators
PharmaEssentia
Responsible party
Sponsor
First posted
May 24, 2017
Start date
May 9, 2017
Primary completion
Nov 22, 2018
Completion
Nov 22, 2018
Results posted
Jul 8, 2020
Last update
Mar 12, 2025

Study contacts

Tsu-Yi Chao, MD, DMS, PhD
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oraxol

Start the discussion